JeanmMarie Guenot, found here on Facebook, is a pharmaceutical business executive who has an impressive 20 years of experience in the industry. She has worked with companies in all stages of their progress, big or small. She excels in corporate and commercial development, business development, project and alliance management, and venture capital activities.
Guenot also has expertise in building and rebuilding companies from scratch. Also excelling in major therapeutic areas such as in her most recent position as the key operating officer at SKS Ocular where she works in ophthalmology. She has an outstanding employment track record working with various companies. The companies in the likes are SKS Ocular LLC which she founded and was the first employee of, Guenot LLC where she was a managing partner, and PDL BioPharma where she served as Vice President of corporate and business development.
The Astounding track record doesn’t stop there as she has also worked at Atlas Venture as an associate in life sciences and at Hoffman-La Roche where she held the coveted position of team leader and principal scientist. JeanMarie Guenot also received a superb education at the University of Pennsylvania, the Wharton School where she received her MBA. Effectively preparing her for all of the business ventures she went on to pursue. As if that isn’t impressive enough, she received her PhD from the University of California in San Francisco in 1993.
Guenot is currently serving at Amphivena Therapeutics where she holds the position of President and CEO. Amphivena Theraputics has taken matters into their own hands developing innovative bi-functional antibody therapies for hematologic malignancies. Their research and development has led to therapies that address blood cancer indications that have unmet medical needs. It is safe to say JeanMarie Guenot is one of the most hard working CEO’s and business executives out there. Her list of LinkedIn credits continue to grow, making Jeanmarie one of the most sought after medical professionals.